Keynote

**Speaker:** Joshua Denny, M.D., M.S. Chief Executive Officer of the National Institutes of Health’s *All of Us* Research Program

*All of Us* Research Program: Improving Health Through Technology, Huge Cohorts and Precision Medicine

The *All of Us* Research Program launched May 6, 2018 and currently has over 400,000 participants who have contributed biospecimens, health surveys, and a willingness to share their EHR. In May 2020, the program launched the beta version of the Researcher Workbench, where registered researchers can access individual-level data and a suite of tools to analyze these data. *All of Us* is committed to catalyzing a robust ecosystem of researchers and providing a rich dataset that drives discovery and improves health.

Panel: Challenges in Mining Adverse Drug Reactions

Coordinator: Dr. Lynette Hirschman  
Chair: Dr. Martin Krallinger, Barcelona Supercomputing Center

Panelists:  
- CDR Monica Muñoz, FDA CDER  
- Prof. Özlem Uzuner, George Mason University  
- Dr. Raul Rodriguez-Esteban, Roche Pharmaceuticals  
- Prof. Graciela Gonzalez-Hernandez, U Pennsylvania Medical School

The BioCreative organizers have convened this panel to explore the possibility of a future BioCreative evaluation on mining adverse drug reactions (ADRs). The panel will explore challenges of mining ADRs, focusing on applications (e.g., post-market surveillance, early warning from tracking social media, predictive models of toxic endpoints for chemicals and drugs, pre-clinical and clinical research) and data sources (including their limitations and accessibility).